On December 2, 2014 the Judicial Panel on Multidistrict Litigation (JPML) will hear oral argument to transfer the currently pending Xarelto cases against Bayer Pharmaceuticals and Janssen Pharmaceuticals to the U.S. District Court for the Southern District of Illinois. The current suits allege the manufacturers failed to warn the public about the dangers of Xarelto.
Xarelto® may increase the risk for life-threatening side effects, including uncontrollable bleeding events and blood clots.Pennsylvania researchers recently published a study that emphasizes the dangers of excessive bleeding associated with anticoagulants. The search for a cure for Xarelto brain bleeds and bleeding events caused by other similar-acting blood thinners has kept researchers busy since Pradaxa entered the market in late 2010. The makers of Xarelto and Pradaxa are now facing lawsuits across the country based on excessive bleeding injuries.There are at least 21 Xarelto bleeding lawsuits pending in 10 different federal district courts across the country. Each of these Xarelto lawsuits alleges that the anticoagulant caused users to develop severe, and sometimes fatal, internal bleeding injuries.
In general, Xarelto lawsuits are filed individually by each plaintiff and are not class actions. If you or a family member have experienced bleeding or blood clots from Xarelto, please call us (Tennessee Xarelto Lawyer) at 1-800-394-2119 or click here to contact us for a confidential case review. 
Overview of Xarelto Complications
Xarelto (Rivaroxoaban) was released in 2011 to join the line of a new generation of anticoagulants that were supposed to surpass Warfarin (Coumadin). These drugs were advertised to be faster, have greater efficiency, and did not require constant blood monitoring by doctors. While patients and physicians attested to the drugs’ strength, it was soon discovered that these medications sometimes worked a little too well. Throughout the country, numerous patients reported suffering uncontrollable internal bleeding injuries after taking Xarelto and other new anticoagulants. While the mechanism of blood-thinning worked in preventing stroke, physicians realized that there was no reversal agent for these medications. Warfarin has a remedy solution in the case of internal bleeding while Xarelto does not.
Overview of Xarelto Complications
Xarelto (Rivaroxoaban) was released in 2011 to join the line of a new generation of anticoagulants that were supposed to surpass Warfarin (Coumadin). These drugs were advertised to be faster, have greater efficiency, and did not require constant blood monitoring by doctors. While patients and physicians attested to the drugs’ strength, it was soon discovered that these medications sometimes worked a little too well. Throughout the country, numerous patients reported suffering uncontrollable internal bleeding injuries after taking Xarelto and other new anticoagulants. While the mechanism of blood-thinning worked in preventing stroke, physicians realized that there was no reversal agent for these medications. Warfarin has a remedy solution in the case of internal bleeding while Xarelto does not.
